

3. Ulusoy S, Ozkan G, Sönmez M, Mungan S, Kaynar K, Cansiz M, et al. Absence of hypoalbuminemia despite nephrotic proteinuria in focal segmental glomerulosclerosis secondary to polycythemia vera. *Intern Med.* 2010;49: 2477-80.
4. Yin Q, Yang Y, He T, Lai C, Liang Y, Jiang W, et al. A case of focal segmental glomerulosclerosis syndrome secondary to high-altitude polycythemia. *Ren Fail.* 2014;36: 108-10.
5. Chen YC, Yeh JC, Chen HS, Hsu HC. Secondary polycythemia associated with membranous nephropathy. *Clin Nephrol.* 1990;33:148-51.
6. Lim CS, Jung KH, Kim YS, Ahn C, Han JS, Kim S, et al. Secondary polycythemia associated with idiopathic membranous nephropathy. *Am J Nephrol.* 2000;20: 344-6.
7. Balal M, Seyrek N, Karayaylali I, Paydas S. A unique form of polycythemia associated with minimal change disease. *Med Princ Pract.* 2004;13:366-8.
8. Karunaratne S, Udayakumara Y, Govindapala D, Fernando H. Medullary nephrocalcinosis, distal renal tubular acidosis and polycythaemia in a patient with nephrotic syndrome. *BMC Nephrol.* 2012;13:66.

Manuel Heras <sup>a,\*</sup>, Ana Saiz <sup>b</sup>, Belén Rosado <sup>c</sup>, María José Fernández-Reyes <sup>a</sup>, José Antonio Queizán <sup>c</sup>, Ramiro Callejas <sup>a</sup>, Álvaro Molina <sup>a</sup>, Leonardo Calle García <sup>a</sup>

<sup>a</sup> Servicio de Nefrología, Hospital General de Segovia, Segovia, Spain

<sup>b</sup> Servicio de Anatomía Patológica, Hospital Ramón y Cajal, Madrid, Spain

<sup>c</sup> Servicio de Hematología, Hospital General de Segovia, Segovia, Spain

\* Corresponding author.

E-mail address: manuhebe@hotmail.com (M. Heras).

2013-2514/© 2015 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

<http://dx.doi.org/10.1016/j.nefroe.2015.08.007>

## Ibuprofen-induced acute interstitial nephritis in the paediatric population<sup>☆</sup>

### Nefritis intersticial aguda por ibuprofeno en población pediátrica

To the Editor,

Acute tubulointerstitial nephritis (ATIN) leads to acute kidney damage; it has a low incidence in the paediatric population<sup>1,2</sup> and is present in up to 15% of renal biopsies performed in adults for acute kidney damage.<sup>3</sup> Currently, the most common cause of ATIN is drugs. Other causes include infection, immunological disease (such as systemic lupus erythematosus or Sjögren's syndrome), and sometimes the cause is unknown.<sup>4</sup> Several groups of drugs have been identified as ethiopathological agents: antibiotics and non-steroidal anti-inflammatory drugs (NSAIDs), which are extensively used in routine clinical practice, are among the most frequently implicated in ATIN.<sup>5</sup>

We present 3 cases of paediatric patients with non-oliguric acute kidney damage, seen in our department between 2008 and 2010, with a working diagnosis of NSAID-induced (ibuprofen) ATIN.

None of the children had a past history of kidney disease or other past medical history of relevance, and all had had blood tests in the previous months with normal creatinine levels and the estimated glomerular filtration rate according to the original Schwartz formula<sup>6</sup> were normal. On physical examination, there were no signs of dehydration, blood pressures were

normal for the patients' age, sex, and height, and there was no oedema. There were no features of obstructive uropathy or evidence of glomerulopathy (C3 and C4 complement study, immunoglobulins, and ANA were normal). The 3 patients had received ibuprofen before developing kidney damage. The patients' clinical characteristics and laboratory results are presented in Table 1.

On admission, ibuprofen treatment was stopped in patients 1 and 3. Patient 2, who was referred from another hospital, had stopped the medication 2 days before admission to our department. Once a diagnosis of ATIN was suspected, treatment was started with intravenous methylprednisolone boluses (15 mg/kg/day for 3 consecutive days, accounting for 250–500 mg iv/day of methylprednisolone) followed by oral prednisolone (starting dose 1 mg/kg/day) at a reducing dose, which was then stopped at 8 weeks. None of the patients had adverse effects attributable to steroids. Urea and creatinine returned to normal levels during the first week in all 3 cases (Fig. 1). Urinary biochemistry and sediment returned to normal within 6 months.

Drug-induced ATIN is the result of a cell-mediated hypersensitivity reaction to a drug. It occurs independently of the route of administration (intravenous, intramuscular, oral, or rectal)<sup>4</sup> and the duration of treatment.<sup>7</sup> Patients who have had

<sup>☆</sup> Please cite this article as: Martínez-López AB, Álvarez Blanco O, Luque de Pablos A, Morales San-José MD, Rodríguez Sanchez de la Blanca A. Nefritis intersticial aguda por ibuprofeno en población pediátrica. *Nefrología.* 2016;36:69-71.

**Table 1 – Clinical details and investigations.**


Case number	1	2	3
Age (years), gender	4, male	12, female	12, female
Weight (kg)	17	38	37
Reason for taking NSAIDs	Urethroplasty	Headache	Appendicectomy
Duration of NSAID (days), dose	5 5 mg/kg/8 h	3 10 mg/kg/8 h	4 10 mg/kg/8 h
Symptoms	Vomiting, abdominal pain, weakness	Macroscopic haematuria and fever	Nausea, vomiting, loss of appetite
Baseline serum creatinine (mg/dL)	0.32	0.50	0.51
Baseline urea (mg/dL)	21	23	20
Maximum creatinine (mg/dL)	2.7	3	1.5
Maximum urea (mg/dL)	140	182	90
Urinalysis	Some isolated red cells and white cells. No eosinophils  Proteinuria with P:Cr ratio of 1.3 mg/mg and tubular component. Osmo 262 mOsm/kg	100+ red cells/field and granular casts. No eosinophils  Proteinuria with P:Cr ratio 1.9 mg/mg and tubular component. Osmo 453 mOsm/kg	1–2 leucocytes and 5–10 red cells/field. No eosinophils  P:Cr ratio 0.3 mg/mg. Osmo 303 mOsm/kg
Renal ultrasound	Kidneys mildly enlarged. Cortical hyperechogenicity and increased corticomedullary differentiation	Diffuse parenchymal hyperechogenicity of both kidneys with loss of corticomedullary differentiation	Diffuse cortical hyperechogenicity

drug-induced ATIN should avoid further exposure to the drug, as recurrence is possible.

The clinical manifestations are variable, and the severity of symptoms varies from asymptomatic urinary abnormalities to acute kidney damage (oliguric or non-oliguric), which may require extra-renal replacement therapy. The classic manifestations (fever, rash, and arthralgia) are present in only 10% of cases<sup>5</sup>; the most common manifestations are non-specific symptoms such as abdominal pain, vomiting, anorexia, weakness, or fever.

Urinalysis may show proteinuria (generally in the non-nephrotic range and predominantly tubular), haematuria, leukocytes, granular hyaline casts, and eosinophils (which are less common in the NSAID-induced ATIN). There may also be other clinical manifestations of tubular injury abnormalities depending on the segment affected (such as glycosuria, bicarbonaturia, tubular acidosis, inability to concentrate urine). A normal sediment does not exclude ATIN.

Ultrasound of the urinary system may show enlarged kidneys and increased echogenicity in the cortex.<sup>8</sup> The gold standard for diagnosis is renal biopsy, which shows inflammatory cell infiltration of the renal interstitium (T lymphocytes, monocytes, macrophages plasma cells, eosinophils) along with local oedema and, occasionally, fibrosis. There may be tubulitis, and the vessels and glomeruli are usually normal.<sup>9</sup> The first step in treatment is to stop the drug responsible and provide adequate supportive treatment for the degree of established kidney damage. Use of corticosteroids as part of the treatment has been debated for years; however, recent publications support their use because they have been demonstrated to improve the prognosis of renal function recovery. Therefore, starting treatment early is the main prognostic marker.<sup>10,11</sup>

**Fig. 1 – Changes over time in urea and creatinine levels.**

Renal biopsy is the investigation of choice to confirm the diagnosis. However, none of our patients underwent biopsy, because they progressed well clinically and biochemically once the responsible agent was stopped (immediately after the

diagnosis was suspected) and corticosteroid treatment was started. The corticosteroid protocol used, by González et al, is described above.<sup>10</sup> The 3 patients showed a rapid response to treatment, and the outcome has been excellent. However, renal biopsy should be considered in cases that are slow to resolve or in case of diagnostic uncertainty.

It is important to explore the past drug history in patients with acute renal failure without previous renal disease or signs of dehydration, and in whom ultrasound of the urinary tract has ruled out obstructive causes. The first step in the treatment of ATIN is to stop the causative drug and provide adequate supportive therapy. Early administration of corticosteroids once a diagnosis is suspected is associated with early resolution of renal failure.

### Conflicts of interest

The authors have no conflicts of interest to declare.

### REFERENCES

1. Nikolic V, Bogdanovic R, Ognjanovic M, Stajic N. Acute tubulointerstitial nephritis in children. *Srp Arh Celok Lek.* 2001;129:S23-7.
2. Schaller S, Kaplan BS. Acute nonoliguric renal failure in children associated with nonsteroidal antiinflammatory agents. *Pediatr Emerg Care.* 1998;14:416-8.
3. Haas M, Spargo BH, Wit EJ, Meehan SM. Etiologies and outcome of acute renal insufficiency in older adults: a renal biopsy study of 259 cases. *Am J Kidney Dis.* 2000;35: 433-47.
4. Alon US. Tubulointerstitial nephritis. In: Avner ED, Harmon WE, Niaudet P, Yoshikawa N, editors. *Pediatric nephrology.* 6th ed. Heidelberg: Springer; 2009. p. 1181-98.
5. Baker RJ, Pusey CD. The changing profile of acute tubulointerstitial nephritis. *Nephrol Dial Transplant.* 2004;19:8-11.
6. Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. *Pediatrics.* 1976;58:259-63.
7. Dharnidharka VR, Araya CE, Henry DD. Acute interstitial nephritis. In: Kiessling SG, Goebel J, Somers MJG, editors. *Pediatric nephrology in the ICU.* Berlin Heidelberg: Springer-Verlag; 2009. p. 193-200.
8. Hiraoka M, Hori C, Tsuchida S, Tsukahara H, Sudo M. Ultrasonographic findings of acute tubulointerstitial nephritis. *Am J Nephrol.* 1996;16:154-8.
9. Ooi BS, Jao W, First MR, Mancilla R, Pollak VE. Acute interstitial nephritis: a clinical and pathologic study based on renal biopsies. *Am J Med.* 1975;59:614-28.
10. González E, Gutiérrez E, Galeano C, Chevia C, de Sequera P, Bermis C, et al. Early steroid treatment improves the recovery of renal function in patients with drug induced acute interstitial nephritis. *Kidney Int.* 2008;73:940-6.
11. González E, Praga M, Grupo Madrileño de Nefritis Intersticiales. ¿Cuándo tratar con esteroides a los pacientes con nefritis intersticial aguda por fármacos? *Nefrologia.* 2009;29:95-8.

Ana Belen Martínez-López <sup>a,\*</sup>, Olalla Álvarez Blanco <sup>a</sup>, Augusto Luque de Pablos <sup>a</sup>, María Dolores Morales San-José <sup>a</sup>, Ana Rodríguez Sanchez de la Blanca <sup>b</sup>

<sup>a</sup> Sección de Nefrología Pediátrica, Servicio de Pediatría, Hospital General Universitario Gregorio Marañón, Madrid, Spain

<sup>b</sup> Servicio de Pediatría, Hospital General Universitario Gregorio Marañón, Madrid, Spain

\* Corresponding author.

E-mail address: [\(A.B. Martínez-López\).](mailto:anabelen.martinez@salud.madrid.org)

2013-2514/© 2015 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).